Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intepirdine - Axovant Gene Therapies/GlaxoSmithKline

Drug Profile

Intepirdine - Axovant Gene Therapies/GlaxoSmithKline

Alternative Names: 742457; GSK 742457; RVT-101; SB-742457

Latest Information Update: 23 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Axovant Sciences; GlaxoSmithKline
  • Class Antidementias; Nootropics
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Dementia; Lewy body disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2018 Axovant Sciences terminates the phase III MINDSET EXTENSION trial for Alzheimer's disease (Treatment-experienced) in USA, Argentina, Australia, Bulgaria, Canada, Chile, Croatia, Czech Republic, France, Germany, Italy, South Korea, Poland, Serbia, Singapore, Slovakia, Spain, Taiwan, and the United Kingdom (PO) (NCT02586909)
  • 13 Feb 2018 Axovant Sciences terminates the phase II/III HEADWAY-DLB Extension trial as intepirdine did not meet its primary efficacy endpoints in the lead-in study RVT-101-2001 for Lewy body disease in USA, United Kingdom, Spain, Netherlands, Canada, France and Italy (PO, Tablet) (NCT02928445)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top